Bone cancer pain
Open Access
- 23 January 2003
- Vol. 97 (S3) , 866-873
- https://doi.org/10.1002/cncr.11144
Abstract
BACKGROUND Bone cancer pain is very common, and patients with this type of pain may be difficult to treat. Development of an experimental model for studying this condition is critical to advancing an understanding of the mechanisms that cause pain in patients with malignant disease. METHODS A murine model of bone cancer was studied. Combined analysis of the extent of tumor-induced bone destruction, pain, and neurochemical characterization of the peripheral and central nervous systems was performed to investigate bone cancer pain. Disease-induced bone destruction was assessed by radiographs and histomorphometry. Pain was assessed by spontaneous and elicited behaviors, and neurochemical analysis involved immunohistochemical detection of hyperalgesic peptides and neurochemical markers. RESULTS Mice with distal femoral sarcomas exhibited behavioral and neurochemical measures of pain. The pain condition created by malignant bone disease was distinct neurochemically from inflammatory and neuropathic pain states. Experimental evidence indicated that both disease-induced osteolysis and tumors themselves contributed to the generation of pain and that peripheral and central sensitization of the nervous system was present. CONCLUSIONS Malignant bone disease creates a unique pain state that involves sensitization of the nervous system. Major contributors to the pain state within the bone tissue are osteoclastic bone resorption and the malignant disease itself. Cancer 2003;97(3 Suppl):866–73. © 2003 American Cancer Society. DOI 10.1002/cncr.11144Keywords
This publication has 58 references indexed in Scilit:
- Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasesCancer, 2000
- Management of cancer painThe Lancet, 1999
- Advances in Cancer PainArchives of Neurology, 1999
- Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 1999
- Effects of the Bisphosphonate Olpadronate in Patients With Carcinoma of the Prostate Metastatic to the SkeletonBone, 1998
- Skeletal complications of malignancyCancer, 1997
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Prostate cancer. Technology versus biologyCancer, 1993
- Character of terminal illness in the advanced cancer patient: Pain and other symptoms during the last four weeks of lifeJournal of Pain and Symptom Management, 1990
- The palliation of symptomatic osseous metastases final results of the study by the radiation therapy oncology groupCancer, 1982